Allogene Therapeutics, Inc. Ratios

Ratios Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin 6,302.03%-225.27%-212,160.26%-344,489.47%-1,168,850.00%
EBIT Margin 5,742.76%-157.94%-215,087.18%-344,986.32%-1,241,813.64%
EBITDA Margin 6,289.43%-162.05%-222,931.41%-335,046.32%-1,166,927.27%
Operating Margin 5,742.76%-157.94%-215,087.18%-344,986.32%-1,241,813.64%
Net Margin 6,298.54%-225.27%-212,160.26%-344,489.47%-1,170,863.64%
FCF Margin 1,426.06%-180.79%-144,685.90%-251,841.05%-913,609.09%
Efficiency
Assets Average 972.82M1,139.33M936.20M732.21M595.77M
Equity Average 854.32M1,002.41M796.04M589.56M467.21M
Invested Capital 629.02M1,079.62M925.20M666.88M512.23M422.18M
Asset Utilization Ratio 0.100.000.000.00
Leverage & Solvency
Interest Coverage Ratio -57.43-0.00M
Equity Ratio 0.880.880.880.810.800.77
Times Interest Earned -57.43-0.00M
Valuation
Enterprise Value 3,447.68M2,636.48M3,783.93M1,669.04M389.76M91.47M154.13M
Market Capitalization 3,447.68M3,167.02M4,611.84M2,126.34M907.08M540.17M446.60M
Return Ratios
Return on Sales 62.99%-2.25%
Return on Capital Employed -0.29%-0.17%-0.38%-0.47%-0.49%
Return on Assets -0.26%-0.23%-0.35%-0.45%-0.43%
Return on Equity -0.29%-0.26%-0.42%-0.56%-0.55%